Product Details
| Product Name:
Levcromakalim |
CAS No.:
94535-50-9 |
| Purity:
99.74% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | Levcromakalim |
| Description | Levcromakalim (BRL 38227) is an activator of the ATP-sensitive K+ channel. |
| In vitro | Levcromakalim inhibits spontaneous contractions completely in a glibenclamide-sensitive manner. LevCromakalim (5 μM) inhibits spontaneous contractions, which are recovered by glibenclamide. Levcromakalim (1, 5 and 10 μM) inhibits phasic contractions to 34±21.1%, 20.1±20.0% and 0% of the control. Glibenclamide reverses the inhibition of spontaneous isometric contractions caused by LevCromakalim (5 μM) to 84±1.5% of the control. Levcromakalim (20 and 100 μM) also inhibits oxytocin (OXT) (10 nM)-induced phasic contractions to 34±21.4% and 14±12.6% of the control [2]. LevCromakalim induces dose-dependent relaxation in both the young and old mesenteric artery (MAs); there is no difference in relaxation with age. However, the relaxation is markedly reduced in response to the high-salt (HS) diet in the old MAs (P<0.05). Maximum dilations to Levcromakalim (10-4 M) are 97 ± 3% in the young MAs versus 98 ± 1% in the young salt arteries, while dilations are 99±0.7% in the old MAs when compared with 85 ± 5% in the old salt arteries (P<0.05) [3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : Insoluble
DMSO : 50 mg/mL (174.62 mM )
|
| Keywords | Potassium Channel | KcsA | BRL38227 | Inhibitor | Levcromakalim | inhibit | BRL-38227 | Cromakalim |
| Inhibitors Related | Minoxidil sulfate | Glibenclamide | (±)-Naringenin | Tolbutamide | Tetraethylammonium bromide | Halothane | Butamben | Cloperastine hydrochloride | 2,2,2-Trichloroethanol | Indapamide |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Neuroprotective Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Potassium Channel Targeted Library | Ion Channel Targeted Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:77529-42-1
$788.00 / 100mg
-
-
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States